Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHA) EBT Margin (2019 - 2025)

Historic EBT Margin for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to 807.14%.

  • Innate Pharma's EBT Margin fell 5147300.0% to 807.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 130.79%, marking a year-over-year decrease of 1306100.0%. This contributed to the annual value of 245.87% for FY2024, which is 2335900.0% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's EBT Margin is 807.14%, which was down 5147300.0% from 360.45% recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's EBT Margin ranged from a high of 1.61% in Q2 2023 and a low of 807.14% during Q2 2025
  • In the last 5 years, Innate Pharma's EBT Margin had a median value of 292.4% in 2024 and averaged 258.86%.
  • As far as peak fluctuations go, Innate Pharma's EBT Margin soared by 3423600bps in 2022, and later crashed by -5147300bps in 2025.
  • Quarter analysis of 5 years shows Innate Pharma's EBT Margin stood at 342.48% in 2021, then surged by 100bps to 0.12% in 2022, then crashed by -9351bps to 11.05% in 2023, then crashed by -3162bps to 360.45% in 2024, then plummeted by -124bps to 807.14% in 2025.
  • Its EBT Margin stands at 807.14% for Q2 2025, versus 360.45% for Q4 2024 and 292.4% for Q2 2024.